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Clinical / Scientific note
Venlafaxine induCed-myoClonuS in 
a patient with mixed dementia
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Myoclonus is a clinical sign defined as sudden, brief, 
shock like, involuntary movements caused by muscular 
contractions or inhibitions1. Certain commonly prescribed 
drugs cause movements disorders as myoclonic jerks and 
polymyoclonus in the absence of other signs of toxicity2. 
Venlafaxine is a serotonin-norepinephrine reuptake inhib-
itor used for the treatment of depression, post traumat-
ic stress disorder, obsessive compulsive disorders, chron-
ic pain and menopausal symptoms3,4. 
We report a case of myoclonus induced by venlafax-
ine in a patient with mixed dementia.
CaSe 
A seventy-five-year-old female presented to neurologic con-
sultation at emergency department complaining of tremors and 
abnormal movements that started 4 days before the admission. It 
started in the four limbs and face at the same time, and accord-
ing to her daughter, they were shock like, abrupt and nonrhyth-
mical. The patient denied any similar events before. The move-
ments could not be suppressed. Her medical history showed 3 
minor strokes, but no sequelae, hypertension and a mixed de-
mentia which was diagnosed 3 years before. She needed some 
help for common activities such as bathing and taking medica-
tions due memory problems. For the treatment of dementia she 
was receiving galantamine 8 mg twice a day and risperidone 1mg 
per day for almost 10 months. She also received enalapril 20 mg 
and aspirin 100 mg per day. Twelve days before the admission, 
her physician prescribed venlafaxine 75 mg per day for depres-
sion. She denied other medications, fever or cough. 
Physical examination showed an arterial pressure of 130 per 
80 mmHg and regular cardiac rhythm. She was alert and cooper-
ative. There was no face rubor. Myoclonus was present in inferior 
limbs, superior limbs and face. There were no signs of parkinson-
ism. Motor strength, sensory functions and language were pre-
served but she presented snout and palmomentonian reflexes. 
Her Mini Mental was 13. Blood count, blood chemistry in-
cluding glucose, sodium, potassium and calcium levels was nor-
mal. Urinalysis excluded infection. We also performed a CT scan 
which did not show evidence of stroke. 
We decided to stop venlafaxine and after 3 days the myoc-
lonus ceased.
diSCuSSion
It is well described in the current literature the asso-
ciation of myoclonus with anticonvulsivants, antidepres-
sants, antipsychotic, cephalosporin and carbapenem anti-
biotics2,4,5. Although our patient was receiving risperidone, 
we believe that myoclonus was induced by venlafaxine, 
once there was a complete remission after discontinuation 
of the drug. Venlafaxine was associated with other move-
ments disorders as blepharoespams2 and myoclonus in the 
setting of serotonin syndrome, which is a potentially fatal 
complication of the combined use of agents that enhance 
serotonin activity3, but we couldn´t find any report of 
myoclonus and venlafaxine without serotonin syndrome. 
Degenerative diseases might present with myoclonus, 
but the myoclonus seen in some of these disorders has 
been primarily limited to small-amplitude jerks of the 
distal limbs (predominantly fingers), termed minipolymy-
oclonus. Our patient presented a more generalized and 
prominent myoclonus, that should raise the possibility of 
drug-induced myoclonus6.
We believe that myoclonus was induced by the seroto-
nergic effects of venlafaxine. The relation between sero-
tonin and myoclonus was first documented by Lhermitte7. 
There are several reports of myoclonus and other move-
ments disorders induced by selective inhibitors of sero-
tonin2-4,8-10. In one of them, Lauterbach reported myoclo-
nus induced by fluoxetine in a patient with Pick disease8 
and postulated that might be an underlying hypersensitiv-
ity of 5HT1A receptors in Pick’s disease. Recently upregu-
lation of 5HT1A receptors in hippocampus in mild cogni-
tive impairment was described, as well as reduction in 
the number of receptors 5HT1A in the hippocampus of pa-
tients with Alzheimer disease9,11,12. Thus, it is possible that a 
dysfunction in the serotonin pathway exists in degenera-
tive diseases, which predisposes to serotonin inhibitors-
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induced movement disorders. This is in accordance with 
a review of movement disorders and serotonin reuptake 
inhibitors conducted by Gerber and Lynd, who concluded 
that patients at higher risk may be those with preexist-
ing neurologic disorders and the elderly. Also, the com-
bined use of neuroleptic and serotonin reuptake inhibi-
tors increases the susceptibility of movement disorders10. 
We conclude that older patients, especially those 
presenting degenerative diseases are at risk for move-
ment disorders when serotonin reuptake inhibitors are 
prescribed. One should carefully evaluate patients with 
degenerative disease in use of venlafaxine and other se-
rotonin reuptake inhibitors.
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